Levalbuterol vs. albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis

References

• Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. The Lancet. 2018;391(10131):1706–1717.
   PubMed Web of Science ®Google Scholar
• Jinjuvadia C, Jinjuvadia R, Mandapakala C, et al. Trends in outcomes, financial burden, and mortality for acute exacerbation of chronic obstructive pulmonary disease (COPD) in the United States from 2002 to 2010. COPD. 2017;14(1):72–79.
   PubMedGoogle Scholar
• Zhu B, Wang Y, Ming J, et al. Disease burden of COPD in China: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:1353–1364.
   PubMed Web of Science ®Google Scholar
• Perera PN, Armstrong EP, Sherrill DL, et al. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD. 2012;9(2):131–141. Apr
   PubMedGoogle Scholar
• Li M, Wang F, Chen R, et al. Factors contributing to hospitalization costs for patients with COPD in China: a retrospective analysis of medical record data. COPD. 2018;13:3349–3357.
   Google Scholar
• 2022 GOLD reports – global initiative for chronic obstructive lung disease – GOLD [Internet]. Global initiative for chronic obstructive lung disease – GOLD; 2021 [cited 2021 Nov 22]. Available from: https://goldcopd.org/2022-gold-reports-2/
   Google Scholar
• Chronic obstructive pulmonary disease group of Chinese Thoracic Society, Chronic Obstructive Pulmonary Disease Committee of Chinese Association of Chest Physician. [Guidelines for the diagnosis and management of chronic obstructive pulmonary disease (revised version 2021)]. Zhonghua Jie He He Hu Xi Za Zhi. 2021;44(3):170–205.
   PubMedGoogle Scholar
• Boulton DW, Fawcett JP. The pharmacokinetics of levosalbutamol. Clin Pharmacokinet. 2001;40(1):23–40.
   PubMed Web of Science ®Google Scholar
• Basic information for levosalbutamol hydrochloride nebuliser solution [Internet]. Beijing: National Medical Products Administration; 2019 [cited 2022 May 25]. Available from: https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9MTY2NzkzJml0ZW1JZD1mZjgwODA4MTdjODMxMmM0MDE3YzliYmZjOGRlMDM2MA==
   Google Scholar
• Donohue JF, Parsey MV, Andrews C, et al. Evaluation of the efficacy and safety of levalbuterol in subjects with COPD. COPD. 2006;3(3):125–132. Aug
   PubMedGoogle Scholar
• Donohue JF, Hanania NA, Ciubotaru RL, et al. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. Clin Ther. 2008;30:989–1002.
   PubMed Web of Science ®Google Scholar
• Truitt T, Witko J, Halpern M. Levalbuterol is not more cost-effective than albuterol for COPD-to the editor. Chest. 2003;124(3):1176–1178.
   PubMed Web of Science ®Google Scholar
• Brunetti L, Poiani G, Dhanaliwala F, et al. Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma. Am J Health Syst Pharm. 2015;72(12):1026–1035.
   PubMed Web of Science ®Google Scholar
• Khorfan FM, Smith P, Watt S, et al. Effects of nebulized bronchodilator therapy on heart rate and arrhythmias in critically ill adult patients. Chest. 2011;140(6):1466–1472.
   PubMed Web of Science ®Google Scholar
• Liu G, Hu S, Wu J. [China guidelines for pharmacoeconomic evaluations (2020)]. 1st ed. Beijing: China Market Press; 2020.
   Google Scholar
• Sabatelli L, Seppälä U, Sastre J, et al. Cost-effectiveness and budget impact of routine use of fractional exhaled nitric oxide monitoring for the management of adult asthma patients in Spain. J Investig Allergol Clin Immunol. 2017;27(2):89–97.
   PubMed Web of Science ®Google Scholar
• Briones JR, Talungchit P, Thavorncharoensap M, et al. Economic evaluation of carbetocin as prophylaxis for postpartum hemorrhage in the Philippines. BMC Health Serv Res. 2020;20(1):1–12.
   Web of Science ®Google Scholar
• Rodríguez-Martínez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma. J Asthma. 2013;50(4):410–418.
   PubMed Web of Science ®Google Scholar
• Hertel N, Kotchie RW, Samyshkin Y, et al. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis. 2012;7:183–199.
   PubMed Web of Science ®Google Scholar
• Drug price database [Internet]. Chongqing: db.yaozh.com; 2021 [cited 2021 Jun 22]. Available from: https://db.yaozh.com/yaopinzhongbiao.
   Google Scholar
• Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest. 2003;123(1):128–135.
   PubMed Web of Science ®Google Scholar
• Statistical Communiqué of the People's Republic of China on the 2019 National Economic and Social Development [Internet]. Stats.gov.cn; 2020 [cited 2021 Jun 22]. Available from: http://www.stats.gov.cn/english/PressRelease/202002/t20200228_1728917.html
   Google Scholar
• Instructions for Chengdu Medical Service Projects and Prices (2016 Edition) [Internet]. Chengdu: cddrc.chengdu.gov.cn; 2016 [cited 2021 Jun 22]. Available from: http://cddrc.chengdu.gov.cn/cdfgw/uploads/0921144846hcrbkbixvxv.pdf
   Google Scholar
• CCEMG – EPPI-Centre cost converter [internet]. London: Campbell and Cochrane Economics Methods Group (CCEMG); 2019 [cited 2022 May 25]. Available from: https://eppi.ioe.ac.uk/costconversion/
   Google Scholar
• Gulácsi L, Rencz F, Péntek M, et al. Transferability of results of cost utility analyses for biologicals in inflammatory conditions for central and eastern European countries. Eur J Health Econ. 2014;15 Suppl 1:S27–S34.
   PubMed Web of Science ®Google Scholar
• Castro Jaramillo HE, Moreno Viscaya M, Mejia AE. Cost-utility analysis of primary prophylaxis, compared with on-demand treatment, for patients with severe hemophilia type a in Colombia. Int J Technol Assess Health Care. 2016;32(5):337–347.
   PubMed Web of Science ®Google Scholar
• Index [Internet]. Stats.gov.cn; 2011 [cited 2021 Jun 22]. Available from: http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htm
   Google Scholar
• Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176(8):753–760.
   PubMed Web of Science ®Google Scholar
• Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018;6(6):421–430.
   PubMed Web of Science ®Google Scholar
• Singh M, Duarte AG, Hsu E-S, et al. Trends and factors associated with nebulized therapy prescription in older adults with chronic obstructive pulmonary disease from 2008 to 2015. J Aerosol Med Pulm Drug Deliv. 2020;33(3):161–169.
   PubMed Web of Science ®Google Scholar
• Yang F. [Cost analysis of 3849 patients with chronic obstructive pulmonary disease with acute exacerbation]. Chinese Med Rec. 2020;21(7):53–56.
   Google Scholar
• Datta D, Vitale A, Lahiri B, et al. An evaluation of nebulized levalbuterol in stable COPD. Chest. 2003;124(3):844–849.
   PubMed Web of Science ®Google Scholar
• Ozminkowski RJ, Wang S, Long SR. The impact of nebulized levalbuterol on health care payments for elderly asthma and chronic obstructive pulmonary disease patients in medicaid plans. Dis Manage Health Outcomes. 2007;15(1):41–55.
   Google Scholar
• Quinn C. The cost effectiveness of levalbuterol versus racemic albuterol. Am J Manag Care. 2004;10(5 Suppl):S153–S157.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lin YX. [Risk factors analysis for one-year and long-term mortality in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease]. Zhonghua Jie He He Hu Xi Za Zhi. 2019;42(12):895–900.
   PubMedGoogle Scholar
• Carson SA, Kallen AN. Diagnosis and management of infertility: a review. JAMA. 2021;326(1):65–76.
   PubMed Web of Science ®Google Scholar
• Mullerova H, Maselli DJ, Locantore N, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest. 2015;147(4):999–1007.
   PubMed Web of Science ®Google Scholar